Type 2 diabetes and obesity

Women with a history of gestational diabetes have a significantly increased risk for long-term mortality regardless of whether or not they subsequently developed type 2 diabetes.

Younger age at type 2 diabetes diagnosis is associated with shorter life expectancy, with 3 to 4 years lost for every decade of earlier diagnosis.

Patients undergoing gastric bypass experience superior patient-reported outcomes, diabetes remission rates and weight loss compared with sleeve gastrectomy.

Improved glycemic control and weight loss seen with the coadministration of cagrilintide and semaglutide in a phase 2 trial.

SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes.

Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.

The 5-year DiRECT results show sustained type 2 diabetes remission for 13% of the intervention group.

Restricting fast-day eating to the morning has a positive effect on postprandial glucose versus standard calorie restriction among people at increased risk for type 2 diabetes who are trying to lose weight, a study shows.

The incidence and burden of type 2 diabetes in young people aged 15–39 years are increasing worldwide, show data from the Global Burden of Disease Study.

A randomized trial reveals benefits of intermittent fasting, without an increased risk for severe hypoglycemia, in people with insulin-treated type 2 diabetes.

Randomized trial findings show reduced glycated hemoglobin and bodyweight in people with type 2 diabetes following a calorie-unrestricted low-carbohydrate, high-fat diet versus a high-carbohydrate, low-fat approach.

Levels of the inflammatory marker C-reactive protein decrease in people with or without type 2 diabetes taking weekly semaglutide 2.4 mg, shows analysis of three STEP trials.

Researchers find that controlling modifiable risk factors limits the risk for developing type 2 diabetes in women with previous gestational diabetes, even if they have overweight or high genetic risk.

The findings of the ReTUNE study show that losing a substantial amount of weight can reverse type 2 diabetes even in people who are only mildly overweight.

The highest risk for type 2 diabetes occurs in people who progress from a low body size in childhood to a high body size in adulthood, shows an analysis of data from the UK Biobank.

Study findings published in JAMA Network Open suggest that for people with class 1 obesity, sleeve gastrectomy is associated with greater weight loss and diabetes remission than lifestyle intervention, but the procedure is also linked to increased incidence of substance use disorder and self-harm.

People with mild-to-moderate obesity who undergo minimally invasive endoscopic sleeve gastroplasty in addition to lifestyle intervention achieve greater weight loss and metabolic improvements than those undergoing lifestyle modification alone, show the MERIT trial results.

Researchers have characterized an atypical form of diabetes in Indian men with low BMI, which has a unique metabolic profile setting it apart from type 1 and type 2 diabetes.

Researchers report that metabolic abnormalities begin to increase at levels of liver fat commonly regarded as normal.

Adding a weekly semaglutide injection in people already using basal insulin to treat type 2 diabetes avoids the need for prandial insulin, show the SUSTAIN 11 findings.